A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy
Macular Degeneration

Interventions

DRUG: 400 µg Brimonidine Implant
OTHER: Sham

Sponsor

Allergan